Sponsors (2)
This is not an official government website.
Copyright © 2026 PLEJ LC. All rights reserved.
Makes major, detailed changes to the federal 340B drug discount program to increase transparency, tighten eligibility, require new reporting and audits, limit contract pharmacy arrangements and third‑party payments, create a claims data clearinghouse, and require patient affordability protections. It adds civil monetary penalties, new registration and recordkeeping rules, Secretary-directed audits, and deadlines for data submissions, with many provisions enforced by the HHS Office of Inspector General. The bill phases in multiple new requirements (reporting, child‑site registration, clearinghouse creation, claims modifiers, and sliding fee caps), imposes repayment and interest for ineligible purchases, and preempts state laws that conflict with the 340B statute. Many changes take effect within months to a year; the general effective date is one year after enactment unless a different date is specified.
The bill increases transparency and enforcement to better target 340B savings to low‑income patients and prevent improper discounts, but does so through extensive reporting, centralized data systems, tight rules, and heavy penalties that raise substantial administrative costs, privacy risks, and financial exposure for safety‑net providers—potentially reducing access for some vulnerable communities.
Low‑income, uninsured, Medicaid and Medicare patients will generally pay less at the point of sale (including $0 for those under poverty and capped copays for other low‑income brackets) and retain access to 340B discounts at covered sites and contract pharmacies.
The bill requires broad, site‑ and drug‑level transparency (public, machine‑readable reporting and registries), giving regulators, payors, researchers, and the public better data to detect misuse and evaluate whether discounts reach intended patients.
Stronger enforcement mechanisms and clearer audit/removal procedures will help recover improper discounts and remove ineligible entities, protecting program integrity and preserving savings for eligible providers and taxpayers.
Hospitals, safety‑net providers, contract pharmacies, state agencies and payors will face large new administrative, IT, and reporting burdens (site/drug/claims‑level reporting, clearinghouse connections, annual certifications) that will raise operating costs and divert staff time from patient care.
The bill imposes significant financial liability risks — retroactive repayment obligations, high per‑claim/per‑day civil monetary penalties (many indexed), compounded interest and other fines — that could threaten the financial stability of smaller safety‑net hospitals and pharmacies.
Stricter eligibility tests, charity/Medicaid share thresholds, limits on contract pharmacies, telehealth documentation rules, and frozen regulatory references risk excluding some hospitals, clinics, subgrantees, or telehealth patients — reducing access to discounted drugs and services for vulnerable or rural populations.
Introduced September 10, 2025 by Buddy Carter · Last progress September 10, 2025